The Controlling Nutritional Status (CONUT) Score is a Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with First-Line Platinum-Based Chemotherapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Controlling Nutritional Status (CONUT) Score is a Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with First-Line Platinum-Based Chemotherapy
Authors
Keywords
-
Journal
Bladder Cancer
Volume -, Issue -, Pages 1-9
Publisher
IOS Press
Online
2020-12-02
DOI
10.3233/blc-200354
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
- (2020) Matthew H. Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
- (2019) Padmanee Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic significance of the controlling nutritional status (CONUT) score in advanced urothelial carcinoma patients
- (2019) Hiroaki Suzuki et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Preoperative controlling nutritional status (CONUT) score as a predictor of long-term outcome after curative resection followed by adjuvant chemotherapy in stage II-III gastric Cancer
- (2018) Xuechao Liu et al. BMC CANCER
- Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes
- (2018) Matthew D. Galsky et al. EUROPEAN UROLOGY
- Targeting the IL-6/JAK/STAT3 signalling axis in cancer
- (2018) Daniel E. Johnson et al. Nature Reviews Clinical Oncology
- Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma: A Multi-institutional Study
- (2018) Norifumi Harimoto et al. ANNALS OF SURGICAL ONCOLOGY
- Prognostic impact of the Controlling Nutritional Status score following curative nephrectomy for patients with renal cell carcinoma
- (2018) Yangqin Zheng et al. MEDICINE
- Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study
- (2018) Marie Warny et al. PLOS MEDICINE
- TNF-α and cancer cachexia: Molecular insights and clinical implications
- (2017) Hetal J. Patel et al. LIFE SCIENCES
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidemiology of Locally Advanced or Metastatic Urothelial Cancer In The US, Europe And Japan
- (2017) M Bharmal et al. VALUE IN HEALTH
- Prognostic impact of controlling nutritional status score in resected lung squamous cell carcinoma
- (2017) Gouji Toyokawa et al. Journal of Thoracic Disease
- The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study
- (2016) Takahiro Toyokawa et al. BMC CANCER
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- T-cell exhaustion in the tumor microenvironment
- (2015) Y Jiang et al. Cell Death & Disease
- Impact of the Preoperative Controlling Nutritional Status (CONUT) Score on the Survival after Curative Surgery for Colorectal Cancer
- (2015) Yasuhito Iseki et al. PLoS One
- Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
- (2014) A. R. de Biasi et al. CLINICAL CANCER RESEARCH
- Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy
- (2013) Matthew D. Galsky et al. CANCER
- Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy
- (2013) Andrea B. Apolo et al. JNCI-Journal of the National Cancer Institute
- Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin
- (2012) Kazutaka Saito et al. BJU INTERNATIONAL
- Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
- (2012) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells
- (2012) Shan Wan et al. PLoS One
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
- (2012) Douglas G. Altman et al. PLOS MEDICINE
- Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
- (2011) W. Joost Lesterhuis et al. JOURNAL OF CLINICAL INVESTIGATION
- Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor
- (2009) M. Hashizume et al. ANNALS OF THE RHEUMATIC DISEASES
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now